The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation
AbstractEpigenetic dysregulation is recognized as a hallmark of cancer. In the last 16 years, a CpG island methylator phenotype (CIMP) has been documented in tumors originating from different tissues. However, a looming question in the field is whether or not CIMP is a pan-cancer phenomenon or a tissue-specific event. Here, we give a synopsis of the history of CIMP and describe the pattern of DNA methylation that defines the CIMP phenotype in different cancer types. We highlight new conceptual approaches of classifying tumors based on CIMP in a cancer type-agnostic way that reveal the presence of distinct CIMP tumors in a multitude of The Cancer Genome Atlas (TCGA) datasets, suggesting that this phenotype may transcend tissue-type specificity. Lastly, we show evidence supporting the clinical relevance of CIMP-positive tumors and suggest that a common CIMP etiology may define new mechanistic targets in cancer treatment. View Full-Text
Share & Cite This Article
Miller, B.F.; Sánchez-Vega, F.; Elnitski, L. The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. Biomolecules 2016, 6, 45.
Miller BF, Sánchez-Vega F, Elnitski L. The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. Biomolecules. 2016; 6(4):45.Chicago/Turabian Style
Miller, Brendan F.; Sánchez-Vega, Francisco; Elnitski, Laura. 2016. "The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation." Biomolecules 6, no. 4: 45.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.